IP Library › Granted Patent US 11,351,169
Granted Patent B2
US 11,351,169 · App. 16/214,355 · Granted Jun 7, 2022

Methods of treating dyskinesia and related disorders

Inventors: John Ciallella (Exton, PA); John Gruner (Exton, PA); Andrew G. Reaume (Exton, PA); Michael S. Saporito (Exton, PA)
Assignee: Melior Pharmaceuticals II, LLC
A61K31/506A61K9/0053A61K31/198A61K31/4245A61K31/4439A61K31/501C07D271/04C07D413/12Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,351,169
App. No.
16/214,355
Granted
Jun 7, 2022
Kind
B2
Abstract

The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.

Claims (9)

1. A composition comprising sydnocarb and an anti-Parkinsonian agent, wherein the anti-Parkinsonian agent is a dopamine agonist, an anti-cholinergic, a monoamine oxidase (MAO) inhibitor, or a catechol-O-methyltransferase (COMT) inhibitor, wherein sydnocarb is not combined with an anti-epileptic agent.

2. The composition of claim 1 , wherein the anti-Parkinsonian agent is a dopamine agonist.

3. The composition of claim 2 , wherein the dopamine agonist is apomorphine, bromocriptine, cabergoline, lisuride, pergolide, ropinirole, pramipexole, or rotigotine.

4. The composition of claim 1 , wherein the anti-Parkinsonian agent is an anti-cholinergic.

5. The composition of claim 4 , wherein the anti-cholinergic is trihyexyphenidyl or benzatropine.

6. The composition of claim 1 , wherein the anti-Parkinsonian agent is a monoamine oxidase (MAO) inhibitor.

7. The composition of claim 6 , wherein the MAO inhibitor is selegiline or ginko biloba.

8. The composition of claim 1 , wherein the anti-Parkinsonian agent is a catechol-O-methyltransferase (COMT) inhibitor.

9. The composition of claim 8 , wherein the COMT inhibitor is tolcapone or entacapone.

Assignments (3)
SECURITY INTEREST Recorded Nov 23, 2021
From: ADHERA THERAPEUTICS, INC.
To: CAVALRY FUND I LP
Reel/Frame 058312/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2019
From: CIALLELLA, JOHN; GRUNER, JOHN; REAUME, ANDREW G.; SAPORITO, MICHAEL S.
To: MELIOR DISCOVERY, INC.
Reel/Frame 050779/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2019
From: MELIOR DISCOVERY, INC.
To: MELIOR PHARMACEUTICALS II, LLC
Reel/Frame 050779/0268 →